Description du projet
Modulation du système immunitaire après un infarctus du myocarde
Les stratégies actuelles de traitement des cardiopathies ischémiques ne font qu’atténuer les symptômes. Le projet MiNeMI, financé par l’UE, travaille sur une nouvelle approche immunomodulatrice visant à réguler l’inflammation et à favoriser la régénération cardiaque après un infarctus du myocarde. Les chercheurs mettent au point un patch cutané non invasif à base de micro‑aiguilles chargé de molécules immunomodulatrices et biologiques. L’idée est de libérer ces produits thérapeutiques dans la couche dermique de la peau, où se trouve un réservoir de cellules immunitaires. L’efficacité et la sécurité de l’approche MiNeMI seront testées in vitro et sur un modèle animal d’ischémie cardiaque.
Objectif
Cardiovascular diseases are the leading global cause of death, being ischemic heart disease one of the deadliest. To date, the conventional therapeutics only ameliorate the state of care of myocardial infarction (MI) patients, and no approved therapy has been developed for heart scars. Promising approaches might come based on the latest knowledge on new pathophysiological concepts, e.g. on the inflammation and immune responses upon MI. The inflammatory phase on MI presents itself as a therapeutic opportunity, with immunomodulation for heart regeneration showing great promise for MI treatment.
Thereby, MiNeMI aims to answer the question if it is possible to modulate the immune system to regulate inflammation and promote heart regeneration through a non-invasive approach. To this end, MiNeMI will, for the first time, develop a novel and unique double-layer biodegradable non-invasive microneedle (MN)-assisted nanovector skin patch, loaded with both immunomodulatory and biologic (cytokines, proteins, and extracellular vesicles) cargos to be tested in a myocardial infarction (MI) disease model. The MN-patch approach proposed here will deliver the cargos into the dermal layer of the skin, a reservoir of immune cells, and will revolutionize the way to regulate the inflammatory systemic immune response upon cardiac ischemia. This MN-assisted nanovector skin patch will be fully characterized in vitro for immune and cardiac effects and also tested in animal MI disease models.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
00014 Helsingin Yliopisto
Finlande